One-time treatment with avigbagene parvec, a gene therapy being developed by Spur Therapeutics, may improve bone health in adults with Gaucher disease. That’s according to data from a now-completed Phase 1/2 clinical trial, GALILEO-1 (NCT05324943), and its ongoing long-term extension study, GALILEO-2 (NCT06545136), showing that…
